ELUT ELUTIA INC.

Nasdaq aziyo.com


$ 0.93 $ 0.03 (2.84 %)    

Monday, 03-Nov-2025 15:59:45 EST
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 0.9352
$ 0.91
$ 0.89 x 52
$ 0.99 x 250
$ 0.91 - $ 0.98
$ 0.85 - $ 5.12
352,694
na
39.65M
$ 0.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-20-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

 elutias-antibiotic-eluting-bioenvelopes-reduce-procedural-difficulty-in-cardiac-device-reoperations-published-in-frontiers-in-cardiovascular-medicine

- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED)...

 lake-street-maintains-buy-on-elutia-lowers-price-target-to-6

Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and lowers the price target from $8 to $6.

Core News & Articles

- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of N...

 elutia-q2-eps-026-misses-017-estimate-sales-6263m-miss-6550m-estimate

Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.17) by 5...

 lake-street-maintains-buy-on-elutia-lowers-price-target-to-8

Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and lowers the price target from $10 to $8.

 elutia-q1-eps-021-misses-020-estimate-sales-603m-miss-665m-estimate

Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5...

 elutia-confirms-that-the-ongoing-global-tariff-environment-has-had-no-material-impact-on-its-commercial-or-operational-performance

Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today conf...

 elutia-to-debut-its-elupro-antibiotic-eluting-bioenvelope-at-hrs-annual-meeting

to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION